39 completed, 8 unknown, 4 terminated, 3 recruiting. 55 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 55 | Completed 39, Unknown 8, Terminated 4, Recruiting 3, Withdrawn 1 |
Follow Prasugrel: new trials by email Literature Review of Prasugrel trials Research Report on Prasugrel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months Prasugrel, Ticagrelor - Myocardial Infarction (MI) | Phase 4 | Recruiting | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 8100 | 2026-09-02 | 2026-09-09 |
| Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) Prasugrel, Clopidogrel - Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI) | Phase 4 | Recruiting | University of Florida | 40 | 2025-10-01 | 2026-10-07 |
| Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy CYP2C19 genotype guided P2Y12 monotherapy, Clopidogrel - Coronary Artery Disease, Platelet Reactivity | Phase 4 | Unknown | St. Antonius Hospital | 88 | 2024-01-23 | 2024-01-26 |
| OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation aspirin - Coronary Artery Disease | Phase 4 | Recruiting | Asan Medical Center | 3944 | 2022-10-21 | 2026-09-17 |
| Clopidogrel Monotherapy in Patients With High Bleeding Risk Clopidogrel, Prasugrel, Tricagrelor - Bleeding Complications | Phase 4 | Completed | Mayo Clinic | 98 | 2022-03-29 | 2024-02-21 |
| Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI Cangrelor, Prasugrel - Coronary Artery Disease, Acute Coronary Syndrome | Phase 4 | Completed | University of Florida | 359 | 2021-02-18 | 2024-03-20 |
| Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE theraputic heparin, prophylactic heparin, P2Y12 - Covid19 | Phase 4 | Completed | Matthew Neal MD | 3591 | 2020-09-04 | 2024-12-30 |
| Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Clopidogrel, Prasugrel, ticagrelor - Coronary Artery Disease | Phase 4 | Completed | University of Florida | 90 | 2019-09-06 | 2023-04-26 |
| Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm Aspirin, Prasugrel, Clopidogrel - Aneurysm, Cerebral, Endovascular Procedures | Phase 4 | Completed | Seoul National University Hospital | 198 | 2018-10-24 | 2022-04-27 |
| Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI) Prasugrel - Acute Coronary Syndrome (ACS) | Phase 4 | Completed | Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company | 204 | 2018-10-16 | 2021-11-12 |
| Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study Prasugrel, Ticagrelor - Coronary Artery Disease | Phase 4 | Completed | University of Florida | 14 | 2018-05-30 | 2020-09-16 |
| Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study Ticagrelor, Prasugrel - Coronary Artery Disease | Phase 4 | Completed | Germano Di Sciascio | 50 | 2017-12-01 | 2022-12-08 |
| Add-on Cangrelor in STEMI-triggered Cardiac Arrest Cangrelor, Placebo, Prasugrel - Cardiopulmonary Arrest With Successful Resuscitation, ACS - Acute Coronary Syndrome | Phase 4 | Unknown | Medical University of Vienna | 60 | 2017-09-01 | 2017-09-13 |
| A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response Ticagrelor, Prasugrel - Diabetes Mellitus | Phase 4 | Withdrawn | CirQuest Labs, LLC | 2017-08-28 | 2020-07-15 | |
| Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI. Cangrelor, Tirofiban, Prasugrel - Coronary Artery Disease, STEMI - ST Elevation Myocardial Infarction | Phase 4 | Completed | Insel Gruppe AG, University Hospital Bern | 122 | 2017-07-04 | 2020-02-21 |
| Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving DAPT Undergoing Dental Procedure. Clopidogrel - Dental Diseases, Antiplatelet Agents | Phase 4 | Unknown | Chiang Mai University | 428 | 2017-05-01 | 2017-04-06 |
| Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel Prasugrel, Ticagrelor - Coronary Artery Disease | Phase 4 | Completed | University of Sao Paulo | 87 | 2017-03-20 | 2022-02-18 |
| Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor Prasugrel, Vorapaxar, Aspirin - Myocardial Infarction | Phase 4 | Completed | University of Florida | 130 | 2016-02-01 | 2020-09-16 |
| Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH) Ticagrelor, Prasugrel, Clopidogrel - Cardiovascular Diseases | Phase 4 | Completed | Erasmus Medical Center | 54 | 2015-12-17 | 2017-02-13 |
| Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention Prasugrel, Clopidogrel - Angina Pectoris | Phase 4 | Terminated | LMU Klinikum | 795 | 2015-09-01 | 2020-07-17 |
Showing 20 of 55. Sign in to see all of them.
Coronary Artery Disease (21) · Acute Coronary Syndrome (18) · Myocardial Infarction (7) · ST Elevation Myocardial Infarction (7) · Cardiovascular Diseases (4) · Hemorrhage (2) · Angina Pectoris (1) · Angina, Unstable (1) · Asthma (1) · COVID-19 (1) · Coronary Disease (1) · Diabetes Mellitus (1) · Heart Arrest (1) · Hypothermia (1) · Infarction (1)
University of Florida (8) · University of Patras (5) · Deutsches Herzzentrum Muenchen (3) · Daiichi Sankyo (2) · LMU Klinikum (2) · Medical University of Vienna (2) · Seoul National University Hospital (2) · Amsterdam UMC, location VUmc (1) · Asan Medical Center (1) · Azienda USL Reggio Emilia - IRCCS (1) · Careggi Hospital (1) · Chiang Mai University (1) · CirQuest Labs, LLC (1) · Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company (1) · David Antoniucci (1)
United States (17) · Italy (8) · Germany (7) · Greece (5) · South Korea (5) · Hungary (4) · Austria (3) · Brazil (3) · Netherlands (3) · Spain (3) · Poland (2) · Switzerland (2) · Belgium (1) · Czechia (1) · Ireland (1)
Dominick J Angiolillo, MD, PhD (4) · Julinda Mehilli, MD (3) · Adnan Kastrati, MD (2) · David Antoniucci, MD (2) · Adriano Caixeta (1) · Alan R Shuldiner, M.D. (1) · Arintaya Phrommintikul, M.D. (1) · Azfar Zaman, MD (1) · Bernd Jilma, MD (1) · Borja Ibanez, MD PhD (1) · Carey Kimmelstiel, MD (1) · Daniel Aradi, MD (1)
PMID 22363016, PMID 22554598, PMID 22646240, PMID 22698488, PMID 22869857, PMID 23169985, PMID 23237136, PMID 23491524, PMID 23500251, PMID 23594617, PMID 23602770, PMID 23735473, PMID 23886748, PMID 24012432, PMID 24291273, PMID 24371012, PMID 24633823, PMID 24768873, PMID 24801283, PMID 24816809, PMID 24890542, PMID 24918960, PMID 25041356, PMID 26010803, PMID 26317618, PMID 26374625, PMID 27012781, PMID 27102290, PMID 27652610, PMID 27823681, PMID 28838475, PMID 28855078, PMID 29154813, PMID 29292242, PMID 29459361, PMID 29544613, PMID 29805112, PMID 30586720, PMID 30636561, PMID 31475799, PMID 32096064, PMID 32122216, PMID 32306797, PMID 32478205, PMID 32527192, PMID 32687741, PMID 32795098, PMID 32882163, PMID 33032712, PMID 33115278
2014 (2), 1OT2HL156812-01 (1), 2008 (1), 2023 (1), U01HL105198 (1)